BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Brief//FDA catalyst calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Brief — FDA catalyst calendar
REFRESH-INTERVAL;VALUE=DURATION:PT6H
X-PUBLISHED-TTL:PT6H
BEGIN:VEVENT
UID:event-147@catalystbrief.girapphe.com
DTSTAMP:20261118T181552Z
LAST-MODIFIED:20261118T181552Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:Readout: Ionis Pharmaceuticals\, Inc. — Olezarsen [Mar 2027]
DESCRIPTION:Phase 3 primary completion: CORE-OLE: A Study of Olezarsen (ISI
 S 678354) Administered Subcutaneously to Participants With Severe Hypertri
 glyceridemia (SHTG).\nSource: https://clinicaltrials.gov/study/NCT05681351
 \nhttps://catalystbrief.girapphe.com/e/147?lang=en\nNot investment advice.
  Dates may change.
URL:https://catalystbrief.girapphe.com/e/147?lang=en
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
